mRNA stocks stand out among RNA modalities: Data Byte

The year has been a big one for mRNA, with the modality proving its worth in COVID-19 development, offering both the fastest path to an authorized vaccine and, so far, the strongest efficacy.

At least five biotechs with mRNA platforms have gone public on NASDAQ and all of them have outperformed the broader biotech market in the past 12 months, even though only two of them — Moderna Inc. (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) — have seen their COVID-19 vaccines validated in Phase III trials. The other three companies have vaccines in earlier stages of development for the indication...